Direct-acting antiviral (DAA) regimens are safe and effective at eradicating hepatitis C virus (HCV) infection. Unfortunately, DAAs remain expensive, so treatment of all HCV-infected patients would substantially affect healthcare costs. It is therefore critical to continue to assess hepatic and extrahepatic benefits of DAA-induced sustained virologic responses (SVRs). DAA-induced SVRs results reduces patients’ risk of cirrhosis and hepatocellular carcinoma and many extra-hepatic manifestations of HCV infection; there are also data that an SVR reduces mortality.